What about role of ticagrelor in secondary prevention of stroke or TIA?
Ticagrelor Not Better Than Aspirin for Preventing CV Events — Physician’s First Watch
Ticagrelor Not Better Than Aspirin for Preventing CV Events
By Amy Orciari Herman
The antiplatelet ticagrelor (Brilinta) is no better than aspirin for preventing cardiovascular events in patients with acute ischemic stroke or transient ischemic attack, the manufacturer announced on Wednesday.
In the international SOCRATES trial, adults aged 40 and older who'd had a stroke or TIA within the past 24 hours were randomized to receive ticagrelor (90 mg twice daily) or aspirin (100 mg once daily) for 90 days. The primary efficacy endpoint was the time to first occurrence of stroke (ischemic or hemorrhagic), myocardial infarction, or death.
The manufacturer said that while fewer endpoint events occurred with ticagrelor, the difference between groups was not statistically significant.